UPDATE: Taglich Brothers Initiates CEL-SCI Corporation at Speculative Buy on Multikine Outlook

Taglich Brothers initiated CEL-SCI Corporation CVM with a Speculative Buy rating. Taglich Brothers commented, "If Multikine secures regulatory clearance and launches in the US and Western Europe by 2018, it should, with relatively modest market penetration and a price per treatment of $50,000, achieve annualized revenue of $700 million (revenue per share of around $1.15) by 2020. … Multikine improves a patient's chance of survival by acting directly to destroy tumors and strengthening the immune system's response to the disease before it is compromised by surgery or radiation/chemotherapy." CEL-SCI Corporation closed at $0.27 on Tuesday.